Almost 1 out of every 3 HealthCare.gov plans want rate hikes of more than 10 percent next year.» Read More
Shares of Regeneron were down about 3 percent after the FDA approved Regeneron's cholesterol-lowering drug Praluent on Friday.
Biogen shares sank after it lowered its 2015 forecast on slower-than-anticipated growth of its multiple sclerosis blockbuster Tecfidera.
Three-D printing could make life a lot easier and affordable for some, Autodesk's Andreas Bastian says.
The world's first malaria vaccine got a green light on Friday from European drugs regulators.
Federal court officers are seeking a unprecedented sentence of life in prison for a peanut company executive convicted of selling salmonella-tainted food. The Associated Press reports.
HealthCare.gov's boss is urging state insurance regulators to consider factors that could weigh against big price increases.
The Centers for Disease Control and Prevention is warning against a salmonella outbreak linked to frozen tuna products.
Eli Lilly chief John Lechleiter tells CNBC all aspects of health care need to be addressed, including the high costs of Obamacare for many Americans.
A new study suggests the idea that more kids are being diagnosed with autism due to reclassification of the issue, NBC reports.
Ebola briefly returned to the headlines this week with a scare at a hospital in New York, but the deadly virus continues to claim victims in West Africa.
Valuation are "very high" in the pharmaceutical sector, Roche CEO Severin Schwan told CNBC on Thursday after the company posted a rise in sales.
A big Supreme Court decision could lead many states to throw in the towel about running an Obamacare exchange.
Hedge funds and and a new type of patent troll are using loopholes in patent law for gains, stifling innovation, says author Joseph Gulfo.
Biogen's Alzheimer's drug showed promise in its latest study, Chief Medical Officer Alfred Sandrock said.
Gilad Glick, CEO of Itamar Medical, explains how his home-test product is trying to cure sleep disorder and heart problems.
Heart device maker St. Jude Medical said it would buy smaller rival Thoratec for $3.4 billion.
A news study shows that women suffering from Alzheimer's worsen twice as fast as their male counterparts, NBC News reports.
Joe Jimenez, Novartis CEO, discusses the pharma company's quarterly results and its new heart failure drug, Entresto.
A man bitten by a rattlesnake this month says he received a $153,000 hospital bill.
While the initial panic or hysteria may have dissipated, the threat of Ebola remains imminent, survivor Kent Brantly said.
Get the best of CNBC in your inbox